Scarica l'app Stockscreener
3.00
1.35%
0.04
Dopo l'orario di chiusura:
3.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.96
Aprire:
$3
Volume 24 ore:
1.98M
Relative Volume:
0.60
Capitalizzazione di mercato:
$327.58M
Reddito:
-
Utile/perdita netta:
$-209.38M
Rapporto P/E:
-1.5985
EPS:
-1.8768
Flusso di cassa netto:
$-179.81M
1 W Prestazione:
+2.74%
1M Prestazione:
-14.77%
6M Prestazione:
-8.81%
1 anno Prestazione:
-52.15%
Intervallo 1D:
$2.95
$3.06
Intervallo di 1 settimana:
$2.87
$3.165
Portata 52W:
$2.19
$5.45
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Nome
Rocket Pharmaceuticals Inc
Settore
Industria
Telefono
646-440-9100
Indirizzo
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
3.00 | 323.21M | 0 | -209.38M | -179.81M | -1.8768 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-18 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-08-20 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-07-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-05-30 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-05-28 | Downgrade | Goldman | Neutral → Sell |
| 2025-05-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-05-28 | Downgrade | Jefferies | Buy → Hold |
| 2025-05-28 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-05-28 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-27 | Downgrade | Needham | Buy → Hold |
| 2025-05-27 | Downgrade | TD Cowen | Buy → Hold |
| 2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
| 2024-12-30 | Iniziato | Wedbush | Outperform |
| 2024-12-18 | Iniziato | Jefferies | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-04-02 | Iniziato | Goldman | Neutral |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-01 | Iniziato | Morgan Stanley | Overweight |
| 2022-11-08 | Iniziato | Canaccord Genuity | Buy |
| 2022-11-01 | Iniziato | BTIG Research | Buy |
| 2022-07-08 | Iniziato | Raymond James | Outperform |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-03-02 | Iniziato | Stifel | Buy |
| 2021-02-18 | Iniziato | Needham | Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-12-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-07-02 | Iniziato | JP Morgan | Overweight |
| 2020-06-25 | Ripresa | BofA/Merrill | Buy |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2019-11-06 | Iniziato | Chardan Capital Markets | Buy |
| 2019-09-26 | Iniziato | Piper Jaffray | Overweight |
| 2019-04-23 | Iniziato | Robert W. Baird | Outperform |
| 2019-03-15 | Iniziato | BofA/Merrill | Buy |
| 2019-02-05 | Iniziato | Oppenheimer | Outperform |
| 2018-09-13 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-07-10 | Iniziato | William Blair | Outperform |
Mostra tutto
Rocket Pharmaceuticals Inc Borsa (RCKT) Ultime notizie
JP Morgan Downgrades Rocket Pharmaceuticals (RCKT) - MSN
Rocket Pharmaceuticals Inc (RCKT) Stock Price, Quote, News & History - Benzinga
RCKT Should I Buy - Intellectia AI
Rocket Pharmaceuticals (RCKT) CEO logs small stock sale to cover RSU tax obligations - Stock Titan
Rocket Pharmaceuticals (RCKT) counsel sells small stake to cover RSU taxes - Stock Titan
Rocket Pharmaceuticals (RCKT) officer sells 384 shares to cover RSU tax withholding - Stock Titan
Rocket Pharmaceuticals (NASDAQ: RCKT) files Form 144 to sell 55,684 shares - Stock Titan
Rocket Pharmaceuticals shareholders approve board nominees and proposals at annual meeting - Investing.com Canada
Rocket Pharmaceuticals shareholders approve board nominees and proposals at annual meeting By Investing.com - Investing.com South Africa
Rocket Pharmaceuticals Shareholders Approve 2026 Governance Proposals - TipRanks
Rocket Pharmaceuticals (RCKT) investors approve directors, pay and option exchange - Stock Titan
Rocket Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Rocket Pharmaceuticals Inc (RCKT) Got Cash. Where’s the Stock Going? - Insider Monkey
Proposed resale of 2,409 Common shares by RCKT filer (Form 144) - Stock Titan
Director resale notice — RCKT (NASDAQ: RCKT) lists 384 shares from vesting - Stock Titan
662-Share Rule 144 Notice for RCKT (NASDAQ: RCKT) - Stock Titan
5 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
Rocket Pharmaceuticals, Inc.Common Stock (NQ: RCKT - The Chronicle-Journal
Rocket Pharmaceuticals (RCKT) Reports Q1 2026 Net Loss of $47.6M - Insider Monkey
5 Best NASDAQ Stocks Under $5 to Buy Right Now - Insider Monkey
Rocket Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript - GuruFocus
RCKT Stock Price, Quote & Chart | ROCKET PHARMACEUTICALS INC (NASDAQ:RCKT) - ChartMill
Rocket Pharmaceuticals CEO Gaurav Shah sells $9,837 in stock - Investing.com UK
Rocket Pharmaceuticals VP John Militello sells $3,083 in stock By Investing.com - Investing.com South Africa
Rocket Pharma general counsel Wilson sells $12,119 in stock - Investing.com UK
Rocket Pharma general counsel Wilson sells $12,119 in stock By Investing.com - Investing.com Nigeria
Rocket Pharmaceuticals CEO Gaurav Shah sells $9,837 in stock By Investing.com - Investing.com Australia
Rocket Pharmaceuticals VP John Militello sells $3,083 in stock - Investing.com
Rocket Pharmaceuticals (RCKT) counsel sells shares to cover RSU tax withholding - Stock Titan
Rocket Pharma (RCKT) CEO sells shares to cover RSU tax obligations - Stock Titan
Rocket Pharmaceuticals (RCKT) insider sells 855 shares for tax withholding - Stock Titan
RCKT (NASDAQ) Rule 144: Director sales listed; 3,361 vested shares - Stock Titan
[144] ROCKET PHARMACEUTICALS, INC. SEC Filing - Stock Titan
RCKT (NASDAQ: RCKT) files Form 144 for 855 vested shares - Stock Titan
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Lifesci Capital Analysts Raise Earnings Estimates for RCKT - MarketBeat
TradingKey - TradingKey
Rocket Pharmaceuticals chief commercial officer sells $67,740 in stock By Investing.com - Investing.com Canada
Rocket Pharmaceuticals chief commercial officer sells $67,740 in stock - Investing.com India
Rocket Pharmaceuticals (RCKT) insider sale covers RSU tax obligations - Stock Titan
Rocket Pharmaceuticals pursues gene therapy advances at Heart Failure 26 to accelerate early diagnosis - Traders Union
RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus - The Globe and Mail
Number of shareholders of Rocket Pharmaceuticals, Inc. – GETTEX:9IP1 - TradingView
Rocket Pharmaceuticals Inc Azioni (RCKT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rocket Pharmaceuticals Inc Azioni (RCKT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Wilson Martin | General Counsel |
May 19 '26 |
Sale |
3.01 |
662 |
1,995 |
677,977 |
| Militello John | See Remarks |
May 19 '26 |
Sale |
3.01 |
384 |
1,157 |
89,780 |
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):